Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Patent expiries and divestitures impact results

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck

4Q Revenues: $10.5 billion (-7%)

4Q Earnings: $7.3 billion (earnings were $781 million 4Q13)

FY Revenues: $42.2 billion (-4%)

FY Earnings: $11.9 billion (earnings were $4.4 billion FY13)

Comments: Pharmaceutical sales were down 4% to $9.4 billion in the quarter. Zetia/Vytorin, Remicade, and Gardasil sales were all down 10% to $1.0 billion, $557 million, and $356 million, respectively. Januvia sales were up 2% to $1.7 billion. Isentress sales were down 5% to $418 million. Nasonex sales were $268 million, down 18%. Singulair sales were up 7% to $319 million. Animal health sales were 885 million, up 2%. Results in the quarter include a 3% negative impact from foreign exchange and a 7% negative impact from patent expiries and divestitures, including the Consumer Care business.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters